RIPE-KG · Version 1.1.0 · Resource
ripekg:work/RIPEWAEB5DB8C4FE9FE6A
https://w3id.org/ripe/ripe-kg/work/RIPEWAEB5DB8C4FE9FE6A
| Subject | Predicate | Object |
|---|---|---|
ripekg:work/10.1016%2Fj.nmni.2025.101692Homologous and heterologous booster of COVID-19 vaccines: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWAEB5DB8C4FE9FE6ASafety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial |
ripekg:work/RIPEWAEB5DB8C4FE9FE6ASafety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial |
dcterms:title |
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial |
ripekg:work/RIPEWAEB5DB8C4FE9FE6ASafety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial |
rdf:type |
node1 |
ripekg:work/RIPEWAEB5DB8C4FE9FE6ASafety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/RIPEWAEB5DB8C4FE9FE6ASafety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial |
rdf:type |
rdfs:Resource |
ripekg:work/RIPEWAEB5DB8C4FE9FE6ASafety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial |
rdf:type |
owl:Thing |
ripekg:work/RIPEWAEB5DB8C4FE9FE6ASafety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial |
rdf:type |
prov:Entity |
ripekg:work/RIPEWAEB5DB8C4FE9FE6ASafety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial |
rdf:type |
ripe:WorkWork |